Does the body actually develop tolerance to boldenone undecylenate over time?

Yes — androgen receptor desensitization is a documented cellular response to sustained ligand exposure. Continued boldenone undecylenate administration beyond the receptor's adaptive threshold leads to AR internalization and reduced mRNA transcription, measurably blunting anabolic output. This is why results from Genesis Bolde 250 typically plateau between weeks 12 and 16 regardless of dose, and why planned off-periods are essential for maintaining long-term responsiveness.

What exactly is androgen receptor desensitization and why does it matter for steroid cycles?

Androgen receptor desensitization refers to the process by which continuous ligand occupancy causes the receptor to be internalized into the cell, suppressing its surface density and transcriptional activity. For cycle planning, this means the anabolic signal generated per unit of boldenone declines progressively with uninterrupted use. Recognizing this ceiling prevents users from misinterpreting stalled gains as a dosing deficiency and escalating unnecessarily, which accelerates rather than resolves desensitization.

Why are structured breaks between boldenone undecylenate cycles recommended from a receptor biology standpoint?

Off-periods allow AR density and sensitivity to recover toward pre-cycle baseline levels. Animal model data on androgen withdrawal shows meaningful AR re-sensitization occurring within four to eight weeks of ligand removal. Without this recovery window, each subsequent cycle starts from a lower receptor-responsiveness baseline, compressing the effective anabolic phase and diminishing cumulative gains over a multi-year training career.

How do I draw an accurate dose from Genesis Bolde 250's 10ml vial using an insulin syringe?

An insulin syringe (1 ml, 100-unit scale) can measure boldenone undecylenate accurately when the conversion is understood: at 250 mg/ml, each 0.1 ml graduation equals 25 mg of active compound. Clean the vial septum with an alcohol swab before each draw, aspirate slowly to avoid air bubbles, and confirm the volume against the barrel markings before withdrawing the needle. Use a separate, larger-gauge drawing needle and swap to a finer injection needle before administering.

What are the correct storage conditions for Genesis Bolde 250 after the vial has been opened?

Store the opened vial at room temperature between 15°C and 25°C (59°F–77°F), away from direct light and moisture. Refrigeration is not required for oil-based injectables and can cause the oil to thicken, making accurate drawing more difficult. Each time the vial is accessed, use a fresh sterile needle to prevent microbiological contamination of the remaining solution. Discard the vial if the solution shows visible particulates, discolouration, or if sterility has been compromised. (2) angle_used

Best seller

Genesis

Bolde 250 250mg/ml 10ml Vial by Genesis

Name: Bolde 250 250mg/ml 10ml Vial by Genesis
Brand: Genesis
SKU: INJ-BOLD-GES-250-008
Price: 46.00 EUR
Availability: InStock

Genesis Bolde 250 is a 250 mg/ml boldenone undecylenate injectable concentrate, supplied in a 10 ml multi-dose vial, formulated specifically to deliver anabolic stimulus while acknowledging that prolonged androgen receptor exposure progressively attenuates cellular response — making structured cycle limits a pharmacological necessity rather than a precaution. The long undecylenate ester sustains plasma-level stability between weekly administrations, supporting consistent receptor engagement without the sharp peaks associated with short-ester preparations. Quality assurance is embedded at every production stage: HPLC potency verification confirms declared concentration accuracy; LAL endotoxin screening certifies injectable-grade sterility; and GMP-compliant fill-and-finish procedures govern each batch released by Genesis.

€46.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Sustains anabolic receptor engagement across a full 12–16 week window without mid-cycle concentration drops.
250 mg/ml concentration enables 25 mg dose increments, allowing fine-tuned receptor load management.
Long undecylenate ester reduces peak-to-trough plasma swings that accelerate receptor saturation.
Non-aromatizing at rates comparable to testosterone, limiting oestrogen-driven receptor interference.
10 ml multi-dose vial format minimises per-dose injection frequency while maintaining supply for a complete protocol.
HPLC-verified potency at batch level ensures every injection delivers the declared 250 mg/ml — eliminating concentration guesswork.
GMP-compliant fill-and-finish process supports consistent sterility across every unit in the batch.

Phase	dosage	Note
Cycle Entry (Weeks 1–4)	300–400 mg/week (1.2–1.6 ml)	Establish plasma levels within the receptor activation range without front-loading, which risks early saturation and accelerated desensitization.
Maintenance Phase (Weeks 5–12)	400–600 mg/week (1.6–2.4 ml)	Hold dose steady rather than escalating; receptor responsiveness is preserved by stable, non-escalating concentrations during this core window.
Cycle Close (Weeks 13–16)	300–400 mg/week (1.2–1.6 ml)	Tapering reduces the abruptness of AR ligand withdrawal and moderates desensitization depth before the mandatory off-period begins.
Off-Period (minimum 4–8 weeks)	0 mg/week	Full ligand removal is required for AR re-sensitization; partial dose maintenance prolongs receptor downregulation and undermines the next cycle's anabolic potential.

Key takeaways

Schedule mandatory off-periods to allow androgen receptor density to fully recover.
Recognize plateau at weeks 12–16 as receptor desensitization, not underdosing.
Avoid escalating dose to compensate for tolerance — it accelerates receptor internalization.
Use 0.4 ml increments at 250 mg/ml for precise, receptor-matched weekly adjustments.
Verify vial integrity and sterility before every draw to protect the injection site.

Boldenone Undecylenate and the Biology of Androgen Receptor Tolerance

Genesis Bolde 250 is a long-ester injectable anabolic agent defined by its capacity to engage skeletal muscle androgen receptors (ARs) at sustained plasma concentrations while simultaneously illustrating a fundamental pharmacological ceiling: chronic, uninterrupted AR activation triggers receptor desensitization mechanisms that progressively reduce the magnitude of anabolic signaling. Receptor desensitization is not a myth or a bro-science concept — it is a documented cellular adaptation in which continuous ligand occupancy leads to AR downregulation, reduced AR mRNA transcription, and impaired nuclear translocation of the AR–ligand complex. Compared to short-ester androgens with frequent peak-trough fluctuations, a stable-release compound like boldenone undecylenate actually prolongs the window of meaningful receptor sensitivity per cycle, because plasma levels remain within the optimal activation range rather than spiking above the saturation threshold repeatedly.

How Desensitization Shapes Cycle Length and Off-Period Duration

Androgen receptors desensitize through two measurable pathways: ligand-induced receptor internalization (assessed in radioligand binding studies) and transcriptional suppression of AR gene expression, quantifiable via RT-qPCR on muscle biopsy tissue. Practical cycle data consistently indicates that anabolic returns from boldenone undecylenate plateau between weeks 12 and 16 for most users — a timeframe that aligns with published AR downregulation kinetics rather than arbitrary convention. Genesis Bolde 250 supports an optimal cycle window of 12–16 weeks precisely because the undecylenate ester maintains receptor-saturating concentrations throughout, after which an enforced off-period allows AR density and sensitivity to recover toward baseline. Research on androgen withdrawal in rodent models documents AR re-sensitization occurring within four to eight weeks of ligand removal, providing a mechanistic rationale for the standard cycle-to-off-time ratio.

Receptor Sensitivity Preservation: Practical Implications for Dosing

Preserving receptor sensitivity across multiple cycles requires more than simply stopping and restarting. Dose escalation as a compensatory strategy for perceived tolerance is counterproductive — higher concentrations accelerate receptor internalization rather than reversing it. Genesis Bolde 250, dosed at 250 mg/ml, allows precise weekly volume adjustments (0.4 ml increments per 100 mg step) without requiring concentration changes that could disrupt the receptor-engagement curve established during the first weeks of a cycle. Structuring each cycle with a defined entry dose, a maintenance phase, and a deliberate end-point — rather than extending duration until results stall — is the single most effective technique for maintaining anabolic responsiveness across successive protocols.

Usage

Confirm the vial label reads 250 mg/ml and visually inspect the oil solution for particulates or discolouration before any draw — receptor-targeted dosing accuracy depends on verified concentration.
Disinfect the vial septum with a 70% isopropyl alcohol swab and allow it to dry fully; this prevents introduction of contaminants that could cause local inflammation and confound cycle assessment.
Draw the calculated weekly volume using an 18–21 gauge drawing needle, then replace with a 23–25 gauge injection needle (25–38 mm length for intramuscular depth) before administration.
Administer via intramuscular injection into the glute, vastus lateralis, or deltoid — rotating sites across the cycle reduces local receptor-site inflammation caused by repeated oil depot formation.
Inject slowly (1 ml per 30 seconds) to minimise tissue pressure, aspirate briefly before injection to confirm non-vascular placement, and apply gentle pressure post-injection.
Log each injection date, volume, and site in a training diary; this record enables accurate identification of the week 12–16 plateau window and ensures the off-period is initiated at the biologically optimal point — not arbitrarily.

Warnings

Contraindications: Genesis Bolde 250 is contraindicated in individuals with existing androgen-sensitive conditions including prostate carcinoma, breast carcinoma, and polycythaemia. Women of childbearing potential should not use this product due to virilisation risk. Persons with active hepatic impairment, thrombophilia, or a documented hypersensitivity to sesame or cottonseed oil carrier should avoid injectable boldenone formulations entirely.

Side Effects: Erythropoietin-mediated haematocrit elevation is the most clinically significant concern with prolonged use; haematocrit exceeding 54% materially increases thromboembolic risk. Androgenic effects — acne, accelerated scalp hair loss in genetically predisposed individuals, and sebaceous gland hyperactivity — are concentration-dependent. Endogenous testosterone suppression is moderate but consistent; expect full HPTA suppression within four weeks of cycle initiation at standard doses.

Monitoring: Monitor haematocrit, haemoglobin, serum testosterone, LH, and FSH at baseline and at weeks 6 and 12 of each cycle. Liver enzymes should be assessed as part of a full metabolic panel despite boldenone's non-hepatotoxic classification. Blood pressure and cardiovascular markers, particularly red blood cell count trends, warrant quarterly review during extended protocols.

PCT: Post-cycle therapy with a SERM (tamoxifen 20 mg/day or clomiphene 50 mg/day) should be initiated no earlier than three weeks after the final injection to allow sufficient plasma clearance of the undecylenate ester. A standard four-to-six week SERM protocol supports endogenous testosterone recovery. Gonadotropin support (hCG 500 IU every other day) during the final two weeks of the cycle can reduce the depth of HPTA suppression entering PCT.

Frequently asked questions

Does the body actually develop tolerance to boldenone undecylenate over time?: Yes — androgen receptor desensitization is a documented cellular response to sustained ligand exposure. Continued boldenone undecylenate administration beyond the receptor's adaptive threshold leads to AR internalization and reduced mRNA transcription, measurably blunting anabolic output. This is why results from Genesis Bolde 250 typically plateau between weeks 12 and 16 regardless of dose, and why planned off-periods are essential for maintaining long-term responsiveness.
What exactly is androgen receptor desensitization and why does it matter for steroid cycles?: Androgen receptor desensitization refers to the process by which continuous ligand occupancy causes the receptor to be internalized into the cell, suppressing its surface density and transcriptional activity. For cycle planning, this means the anabolic signal generated per unit of boldenone declines progressively with uninterrupted use. Recognizing this ceiling prevents users from misinterpreting stalled gains as a dosing deficiency and escalating unnecessarily, which accelerates rather than resolves desensitization.
Why are structured breaks between boldenone undecylenate cycles recommended from a receptor biology standpoint?: Off-periods allow AR density and sensitivity to recover toward pre-cycle baseline levels. Animal model data on androgen withdrawal shows meaningful AR re-sensitization occurring within four to eight weeks of ligand removal. Without this recovery window, each subsequent cycle starts from a lower receptor-responsiveness baseline, compressing the effective anabolic phase and diminishing cumulative gains over a multi-year training career.
How do I draw an accurate dose from Genesis Bolde 250's 10ml vial using an insulin syringe?: An insulin syringe (1 ml, 100-unit scale) can measure boldenone undecylenate accurately when the conversion is understood: at 250 mg/ml, each 0.1 ml graduation equals 25 mg of active compound. Clean the vial septum with an alcohol swab before each draw, aspirate slowly to avoid air bubbles, and confirm the volume against the barrel markings before withdrawing the needle. Use a separate, larger-gauge drawing needle and swap to a finer injection needle before administering.
What are the correct storage conditions for Genesis Bolde 250 after the vial has been opened?: Store the opened vial at room temperature between 15°C and 25°C (59°F–77°F), away from direct light and moisture. Refrigeration is not required for oil-based injectables and can cause the oil to thicken, making accurate drawing more difficult. Each time the vial is accessed, use a fresh sterile needle to prevent microbiological contamination of the remaining solution. Discard the vial if the solution shows visible particulates, discolouration, or if sterility has been compromised. (2) angle_used

Manufacturer

Genesis entered the injectable anabolic market from a foundation of pharmaceutical-grade manufacturing infrastructure rather than the compound-and-fill operations that characterised many early-era performance supplement producers. The brand's formative period was defined by a deliberate commitment to a narrow, well-controlled product range: prioritising documented concentration accuracy and batch-to-batch reproducibility over catalogue breadth. Internal quality control at Genesis centres on HPLC potency analysis conducted at the finished-product stage — a practice that distinguishes manufacturers who test end-product from those who rely exclusively on API intake certificates. This approach was instrumental in establishing Genesis among communities where verified potency directly influenced athlete preparation timelines and competition outcomes. Today, Genesis maintains GMP-aligned production standards across its injectable catalogue, with LAL endotoxin testing applied per batch and cold-chain distribution protocols ensuring product integrity from fill-and-finish through to end-user delivery.

Product details

Brand	Genesis
Active ingredient	boldenone undecylenate
Also known as	Equipoise, EQ, Boldenone Undecylenate, Bolde 250, Genesis Equipoise
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-BOLD-GES-250-008

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration